Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo

The therapeutic options for patients with relapsed or metastatic myxoid liposarcoma (MLS) remain scarce and there is currently no targeted therapy available. Inhibition of the HSP90 family of chaperones has been suggested as a possible therapeutic option for patients with MLS. However, the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Vannas, Christoffer, Andersson, Lisa, Dolatabadi, Soheila, Ranji, Parmida, Lindén, Malin, Jonasson, Emma, Ståhlberg, Anders, Fagman, Henrik, Åman, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945459/
https://www.ncbi.nlm.nih.gov/pubmed/35327426
http://dx.doi.org/10.3390/biomedicines10030624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945459/
https://www.ncbi.nlm.nih.gov/pubmed/35327426
http://dx.doi.org/10.3390/biomedicines10030624

Ejemplares similares